Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sienna Biopharmaceuticals, Inc.SNNA · Entity 154554 | Director | May 30, 2019 | June 03, 2019 |
| Tyra Biosciences, Inc.TYRA · Entity 4680 | Director · President and CEO | September 15, 2026 | September 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sienna Biopharmaceuticals, Inc.
Report date May 30, 2019 · Filed June 03, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.22 · Expires 2029-05-30 | Direct | 25,000 |
Reported balance
After 2019-05-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-05-30 · Grant · Acquired 25,000 · Balance 25,000 F1: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, subject to continued service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, subject to continued service through each applicable vesting date.
Tyra Biosciences, Inc.
Report date September 15, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,438,495 |
Reported balance
After 2026-09-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-15 · Grant · Acquired 864 · Balance 1,438,495 F1: These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan. F2: Includes restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan.
F2: Includes restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 07, 2018 Filed Mar 9, 2018 19:00 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | SaleCommon Stock | 3,704 | $20.00 | $74,080.00 |
DisclosureSEC source: 0001140361-18-012906 · doc1.xml · nonDerivative · entry 1 Harris Todd · CIK 0001711463 · Director · Head of Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 628,362 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 22, 2017. Read SEC document |
| July 26, 2017 Filed Jul 27, 2017 16:25 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | GrantStock Option (Right to Buy) · Derivative | 11,926 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001140361-17-028898 · doc1.xml · derivative · entry 1 Harris Todd · CIK 0001711463 · Director · Head of Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,926 Underlying: Common Stock · 11,926 shares Expires 2027-07-26 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on the first anniversary measured from July 26, 2017, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.